“Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India,” tweeted Union Health Minister,Mansukh Mandaviya today.
Johnson and Johnson Pvt Ltd has applied on Friday for Emergency Use Authorization (EUA) of its single-dose COVID-19 vaccine in India.
“Now India has 5 EUA vaccines. And this will further boost nation’s collective fight against Covid-19,” tweet further informed.
The EUA submission is based on topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, which demonstrated that company’s single-shot vaccine was 85 per cent effective in preventing severe disease across all regions studied.
A Johnson and Johnson India spokesperson in a statement further informed that the EUA submission further showed protection against COVID-19 related hospitalisation and death, beginning 28 days after vaccination.
Follow and connect with us on Twitter, Facebook, Linkedin
